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Accumulating evidence has shown the adverse eﬀect of long-term hyperaldosteronism on cardiovascular morbidity that is
independent of blood pressure. However, the diagnosis of primary aldosteronism (PA) remains a challenge for patients who
present with subtle or atypical features or have chronic kidney disease (CKD). SPECT/CT has proven valuable in the diagnosis of
a number of conditions. The aim of this study was to determine the usefulness of I-131 NP-59 SPECT/CT in patients with atypical
presentations of PA and in those with CKD. The records of 15 patients with PA were retrospectively analyzed. NP-59 SPECT/CT
wasabletoidentifyadrenallesion(s)inCKDpatientswithsuspectedPA.PatientsusingNP-59SPECT/CTimaging,comparedwith
those not performing this procedure, signiﬁcantly featured nearly normal serum potassium levels, normal aldosterone-renin ratio,
and smaller adrenal size on CT and pathological examination and tended to feature stage 1 hypertension and non-suppressed
plasma renin activity. These ﬁndings show that noninvasive NP-59 SPECT/CT is a useful tool for diagnosis in patients with
subclinical or atypical features of PA and those with CKD.
1.Introduction
Primary aldosteronism (PA) is the most common cause of
surgically curable secondary hypertension and aﬀects more
than 10% of the general hypertensive population [1]. Stage
2 hypertension according to the Seventh Joint National
Committee (JNC 7) [2] with or without symptomatic
hypokalemia leads to a higher probability of PA detection,
andthediagnosticapproachisstraightforwardinthreesteps:
case-ﬁnding screening testing of elevated plasma aldosterone
concentration (PAC), susppressed plasma renin activity
(PRA),andahighaldosteronetoreninratio(ARR),followed
byaldosteronesuppressionconﬁrmatorytestingandsubtype
studies of computed tomography (CT) imaging, adrenal
vein sampling, or I-6-beta-iodomethylnorcholesterol (I-131
NP-59) scintigraphy. However, normotensive PA patients,
featured as elevated PAC, have been reported [3], and
the ARR is not reliable in patients with chronic kidney
disease (CKD) [4]. Therefore, diagnosing PA can be tricky
when clinical and biochemical features vary widely and the
criteria for PA cannot be met, especially in patients with
CKD or who present with subclinical symptoms featured as2 Journal of Biomedicine and Biotechnology
stage 1 hypertension or are found to have atypical laboratory
testing.
It has been reported that an increased serum aldosterone
levelinnormotensiveindividualsleadstothedevelopmentof
sustained hypertension in the future [5]. Moreover, patients
with PA are at greater risk than those with the same degree
of blood pressure (BP) but without PA for cardiovascular
events and stroke because long-term hyperaldosteronism
leads to vessel and heart damage that is independent of
BP [6]. Therefore, normalization of circulating aldosterone
is the paramount therapeutic goal for PA [7], and timely
identiﬁcation of subclinical or atypical features of PA is of
clinical value.
The common modalities used for subtype identiﬁcation
ofPAalsohavelimitations.AdrenalCTscanisconsideredthe
initial diagnostic modality for the identiﬁcation of adrenal
nodules; however, its diagnostic sensitivity is estimated to be
50%[8].AdrenalCTimagingcannotcorrectlydetectadrenal
microadenoma smaller than 1cm in diameter and bilateral
adrenal hyperplasia, both of which may present normal-
appearing adrenals. Adrenal vein sampling is the diagnosis
of choice to diﬀerentiate unilateral from bilateral disease in
patients with PA; however, this technique is invasive and
diﬃcult to access the right adrenal vein [9] and inevitably
carries some risk of adrenal hemorrhage [10], despite
being performed by an experienced radiologist. Moreover, it
appears to be rarely applied to patients with CKD and an
increased bleeding tendency. Dexamethasone-suppression
NP-59 scintigraphy has a high aﬃnity for adrenocortical
tissue, but traditional planar imaging has low sensitivity and
speciﬁcity for detection of early adrenal activity, especially
adenoma smaller than 1cm in diameter [11]. Therefore,
diagnosis can be challenging in patients who have CKD
or/and present with subclinical symptoms or/and are found
to have atypical laboratory testing or/and negative imaging
studies.
Single photon emission computed tomography
(SPECT)/CT imaging is a signiﬁcant technical innovation
that simultaneously provides anatomic and functional
information to allow for better localization of tracer activity
and to enhance diagnostic accuracy and sensitivity [12].
SPECT/CT has proven valuable in oncology and neurology
[13] and has the advantage of identifying small lesions
demonstrated in several case reports of nephrology [14, 15].
Recently, I-131 NP-59 SPECT/CT has been recommended
as a diagnostic method of choice for patients with clinically
conﬁrmed PA, but inclusive CT or adrenal vein sampling
results, because of its high sensitivity (up to 81.8%) and
diagnostic accuracy [16]. To the best of our knowledge, there
has been no clinical study of the use of NP-59 SPECT/CT in
patients with subclinical or atypical PA or CKD patients with
suspected PA. Thus, this aim of this study was to determine
the usefulness of I-131 NP-59 SPECT/CT in patients with
atypical presentations of PA and in those with CKD.
2.MaterialsandMethods
2.1. Patients. The records of 14 patients with PA (5 males,
10 females) with a median age of 55.9 years (range,
27–72 years) who underwent adrenalectomy at our insti-
tution from April 2007 to April 2010 were retrospectively
reviewed. Patients were followed until October 2010. One
patient who did not undergo adrenalectomy because of
clinically conﬁrmed bilateral adrenal hyperplasia was also
included in the analysis. Therefore, the study included 15
patients, 14 with pathologically conﬁrmed PA, and one with
clinically conﬁrmed PA. Of the 15 patients, 6 who received
NP-59 SPECT/CT imaging served as the SPECT/CT group,
and the other 9 who did not receive NP-59 SPECT/CT
imaging served as the control group. The complete data
of these 15 patients are presented in Tables 1 and 2 and
summarizedinFigure1.Themedianperiodoffollowupwas
216 days (range: 183–527 days). The study was approved by
our Institutional Review Board.
2.2. Data Collection. We collected clinical data including
age, gender, systolic and diastolic BP at admission, chief
complaints,laboratoryresults(serumpotassium[K],plasma
aldosterone concentration [PAC], plasma renin activity
[PRA], aldosterone-renin-ratio [ARR], and transtubular
potassium gradient [TTKG]) or 24-hour urinary potassium
excretion, and conﬁrmatory tests results (including saline
loading test or/and captopril test) if done, followup out-
comes, and imaging and pathological data. PAC and PRA
weremeasuredbycommercialRIAkits(ALDOCTK,#P2714,
Diasorin Inc., MN, USA, and GAMMACOAT PLASMA
RENIN ACTIVITY, #CA-1533, Diasorin Inc., MN, USA,
resp.).NormalrangesforPACandPRAare3.7–24ng/dLand
0.15–2.33ng/mL/h, respectively.
2.3. Deﬁnitions. The deﬁnition of hypertension stage was
based on the JNC 7 classiﬁcations [2], that is, stage 1
hypertension was deﬁned as a BP of 140/90mmHg or
greater, and stage 2 hypertension was deﬁned as a BP of
160/100mmHg or greater. A positive captopril test was
deﬁned as PAC suppression >30% after oral administration
of 25mg of captopril, taken 2 hours before sampling [17]. A
positive saline loading test was deﬁned as PAC > 10ng/dL
after intravenous infusion of 2L of 0.9% saline over 4h
[17]. An ARR > 3 0w a sc o n s i d e r e dt ob ep o s i t i v e[ 10].
All drugs that can aﬀect the ARR were discontinued for 2
weeks before performing conﬁrmatory tests. Symptomatic
hypokalemia was deﬁned as serum K < 3.0mEq/L. A TTKG
> 4 was considered positive for kaliuria. Improvement was
deﬁnedasawell-controlledBPwithnooradecreaseddoseof
antihypertensivemedications,andnormalizationordecrease
of PAC, PRA,and serumK. CKD was deﬁnedas anestimated
glomerular ﬁltration rate (eGFR) < 60mL/min/1.73m2,
based on the National Kidney Foundation Kidney Disease
Outcome Quality Initiative guidelines [18]. Stage 3 CKD was
deﬁned as an eGFR of 30 to 59mL/min/1.73m2.S t a g e4w a s
deﬁned as an eGFR of 15 to 29mL/min/1.73m2.S t a g e5w a s
deﬁned as an eGFR of less than 15mL/min/1.73m2.
2.4. Patient Preparation and NP-59 Planar, SPECT, and
SPECT/CT Imaging. A dexamethasone suppression regimen
(1mg orally 4 times daily) was initiated 7 days beforeJournal of Biomedicine and Biotechnology 3
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SPECT/CT SPECT/CT SPECT/CT
Patient 12
(stage3C K D )
(kaliuria)
Patient 7
(kaliuria)
Screening testing and
conﬁrmatoryt e s t i n g
PAC↑,P R A ↓,A R R ↑
(typical features)
test-p
test-n
test-nd
test-p
test-n
test-n
test-nd
test-nd
PAC↑,P R A — ,A R R ↑
PAC↑,P R A — ,A R R —
PAC—, PRA—, ARR↑
Category1 # (n = 8) Category2 # (n = 2) Category3 # (n = 2) Category4 # (n = 3)
Control Control
(n = 6) (n = 2) Control (n = 2) (n = 1) (n = 1) (n = 3)
CT-p CT-p CT-p CT-p CT-p CT-n CT-n
BP-imp BP-imp BP-imp BP-imp BP-imp BP-not
Pathology-p (n = 14)
∗
Patient 2
(kaliuria) Patient 1, 3
Patient 8
Patient 4
Patient 14
(kaliuria)
(kaliuria)
Patient 10
Patient 9 (kaliuria)
Patient 13
Patient 15
(stage4C K D )
Patient 11
Patient 6
Patient 5 (kaliuria)
Abbreviations: p, positive; n, negative; nd, not done; BP-imp, BP improve; BP-not, BP not improve; ↑,elevate; ↓, suppressed; –– , within normal range;
test, conﬁrmatorytest; other abbreviations are the same as Tables 1 and 2.
Arrow from left to right denotes symptoms presented from severe to mild form; arrow from up to down denotes screening testing from typical to
atypical features.
∗Exclude patient 15 because of bilateral adrenal hyperplasia.
#Four categories wereo rdered by the severity of symptoms: category 1, stage2h y pertension and hypokalemia; category 2, stage1h y pertension and
hypokalemia; category 3, stage1h y pertension and low-normal potassium level; category4 ,s t a ge1h y pertension and normal potassium level.
(Figure 2)
Figure 1: Qualitative analysis of Tables 1 and 2.
tracer injection and this was continued throughout the
imagingprocedureandfor5dayspostinjection[12].Patients
were also given 5 drops daily of Lugol’s solution 3 days
before the start of imaging to block thyroid uptake of
free I-131, and This was continued until the end of the
imaging period. All drugs that can interfere with NP-59
uptake were discontinued for 4 weeks before imaging [12].
NP-59 scanning was performed on days 1 through 5 to
obtain planar images after intravenous injection of 1.5mCi
(56MBq) NP-59. SPECT/CT scanning was performed on
days 2 through 5 with a dural-head gamma camera (DST-
XLi; GE Medical Systems, Buc, France) to obtain SPECT and
merged SPECT/CT images.
2.5.ImagingInterpretation. CTimageswithﬁnecuts(3mm)
wereobtainedandinterpretedbyawell-experiencedradiolo-
gist. The NP-59 planar, SPECT, and SPECT/CT images were
interpreted by 2 nuclear medicine specialists. Aldosteronism
on the aﬀected side(s) was considered if there was early
visualization of the tracer on imaging before the ﬁfth
postinjection day and intense uptake greater than that in the
liver [12].
2.6. Adrenalectomy and Pathological Interpretation. Of the 15
patients, 14 underwent laparoscopic adrenalectomy by an
experienced surgeon. The histopathological examinations of
the surgical specimens were performed by an experienced
pathologist.
2.7. Statistical Analysis. All data are expressed as median
(range). The diﬀerences between the SPECT/CT group and
the control group were compared by Fisher’s exact test
for categorical variables, or by Mann-Whitney U test for
continuous variables. A two-sided P value less than .05 was
considered statistically signiﬁcant. All data were analyzed
using SPSS version 13.0 (SPSS Inc., Chicago, IL).
3. Results
Pathological examination showed that 12 of 15 patients
had unilateral adenomas, 1 had a micronodule, and 1 had
unilateralfocalnodularhyperplasia(Table2).1hadclinically
conﬁrmed bilateral adrenal hyperplasia (Figure 2).
3.1. Diﬀerences of Clinical Pictures between the Control and
SPECT/CT Groups (Table 1). In the control group (n =
9), 6 subjects had stage 2 hypertension along with symp-
tomatic hypokalemia; 2 had stage 1 hypertension along with
symptomatic hypokalemia; one had stage 1 hypertensionJournal of Biomedicine and Biotechnology 5
(a)
96hours
Post-abdomen
(b)
SPECT
(c)
Fused SPECT/CT
(d)
Figure 2: A 27-year-old woman (patient 15) who had stage 4 CKD presented with stage 1 hypertension alone due to bilateral adrenal
hyperplasia, whose PAC was elevated, but whose serum potassium level was normal, whose PRA was nonsuppressive, whose ARR was
negative, whose conﬁrmatory testing was negative, whose bilateral adrenal lesions had normal appearing on CT (a) and faint uptakes on
planar imaging (b) but true positive on SPECT (c) and coronal SPECT/CT (d) imaging. After treatment with 25mg of spironolactone, her
BP and PAC were normalized.
without symptomatic hypokalemia. In the SPECT/CT group
(n = 6), 4 subjects had stage 1 hypertension without
symptomatic hypokalemia; 2 had stage 2 hypertension along
with symptomatic hypokalemia.
3.2. Diﬀerences of Screening Testing and Conﬁrmatory Testing
between the Control and SPECT/CT Groups (Table 1). In
the control group (n = 9), 8 subjects had elevated PAC
a n do n eh a dn o r m a lP A C ;5h a ds u p p r e s s e dP R Aa n d4
had nonsuppressed PRA; 8 had positive ARR and one had
negative ARR; 4 had positive conﬁrmatory testing and 5
had absent results. In the SPECT/CT group (n = 6), 6
subjects had elevated PAC; one had suppressed PRA and
5 had nonsuppressed PRA; 2 had positive ARR and 4 had
negative ARR; 4 had negative conﬁrmatory testing and 2 had
absent results.
3.3. Diﬀerences of Imaging Modalities between the Control
and SPECT/CT Groups (Table 2). CT produced 9 (100%)
true positive results in the control group. CT produced 2
(33%) false negative and 4 (67%) true positive results in
the SPECT/CT group. NP-59 planar imaging produced 2
(33%) true positive and 4 (67%) false negative results. NP-
59 SPECT and SPECT/CT produced 6 (100%) true positive
results, indicating 100% sensitivity.
3.4. Integrated Analysis of All Features between the 2 Groups
(Figure 1). We divided all 15 patients into 4 categories
based on the severity of hypertension and hypokalemia:
category 1 (stage 2 hypertension and hypokalemia; n = 8;
6 in the control group and 2 in the SPECT/CT group);
category 2 (stage 1 hypertension and hypokalemia; n = 2;
all in the control group); category 3 (stage 1 hypertension
and low-normal potassium level; n = 2; 1 in the control
group and 1 in the SPECT/CT group); category 4 (stage
1 hypertension and normal potassium level; n = 3; all in
the SPECT/CT group). The screening testing from typical
to atypical features was ordered from the top to bottom. PA6 Journal of Biomedicine and Biotechnology
Table 2: Imaging and pathological data of study subjects.
Patient Age (y) Gender
CT result NP-59 result Pathological result Followup
improvement Appearance
(side) Size (mm) Planar SPECT SPECT/CT Finding Size
(mm)
Control group (n = 9)
15 0 FN o d u l e ( L ) 2 0 — — —A d e n o m a 2 1 P A C , P R A , K
23 4 FN o d u l e ( L ) 1 8 — — —A d e n o m a 1 6 PAC, PRA, K,
BP
35 8 FN o d u l e ( R )1 7 — — —A d e n o m a 1 7 P A C , P R A , K
43 2 FN o d u l e ( L ) 2 0 — — —A d e n o m a 2 0 P A C , K , B P
57 1 FN o d u l e ( L ) 1 7 — — —A d e n o m a 2 5 PAC, PRA, K,
BP
65 9 M N o d u l e ( L ) 1 1 — — —A d e n o m a 1 0 P A C , B P
76 0 FN o d u l e ( R )2 1 — — —A d e n o m a 2 0P A C , K
87 2 M N o d u l e ( R )2 2 — — —A d e n o m a 2 0 PAC, PRA, K,
BP
95 6 FN o d u l e ( L ) 1 7 — — —A d e n o m a 1 7 P A C , K , B P
SPECT/CT group (n = 6)
10 55 F Normal — N R R Micronodule 0.8 PAC, K, BP
11 48 F Nodule (L) 17 L L L Adenoma 17 PAC, PRA, K,
BP
12† 57 M Enlarge (L) 9( i n
thickness) NLL Focal nodular
hyperplasia 6 PAC, PRA, K,
BP
13 56 M Nodule (L) 12 N L L Adenoma 10 PAC, BP
14 39 M Nodule (R) 14 N R R Adenoma 12 PAC, K, BP
15† 27 F Normal — Faint Bil Bil —# —# PAC, BP
Abbreviations: CT: computed tomography; L: left; R: right; Bil: bilateral; other abbreviations are the same as Table 1.
†Patients 12 and 15 had stages 3 and 4 chronic kidney disease with serum creatinine level of 2.2 and 2.5mg/dL, respectively.
#Patient 15 did not undergo adrenalectomy because of bilateral adrenal hyperplasia.
waseasilydiagnosedfromthetypicalclinicalpresentationsof
stage1or2hypertensionalongwithhypokalemiaandtypical
screening testing followed by positive CT results (patients
1–3, 5, and 8). Despite the presence of atypical screening
testing, PA also could be diagnosed from typical clinical
presentations together with positive CT results (patients 4, 7,
and 9). However, we found that the SPECT/CT group had a
higherpercentageofmildclinicalpresentations,suchasstage
1 hypertension and low-normal or normal serum potassium
level(patients10,11,13,and15),atypicallaboratoryfeatures
of PA (patients 10, 12–15), and negative CT results (patients
10 and 15). All patients were found to have an improvement
of BP after adrenalectomy and/or medical treatment, except
forpatients1,3,and7inthecontrolgroup.Thistableimplies
thatthetimingofusingNP-59SPECT/CTtendstocategories
3 and 4, as well as atypical screening and conﬁrmatory
testing.
3.5. Relationship of NP-59 SPECT/CT Lateralization Results
to Clinical Outcome and to Pathological Features (Table 2 and
Figure 1). NP-59 SPECT/CT correctly identiﬁed 3 adenomas
(median size, 12mm; range 10–17mm), 1 micronodule
(0.8mm in size), 1 focal nodular hyperplasia (with the
largest micronodule 6mm in size), and 1 bilateral adrenal
hyperplasia (Figure 2) in 6 patients. Of these 3 adenomas,
2 were not detected on planar images. 2 (33%) of the
SPECT/CT group had stages 3 and 4 CKD, both of which
had atypical laboratory testing. All 6 patients had a clinical
improvement of BP and normalization of PAC, 4 of whom
had stage 1 hypertension and cured BP.
3.6. Comparison of Parameters between the Control and
SPECT/CT Groups (Table 3). The median level of serum
potassium was signiﬁcantly higher in the SPECT/CT group
than in the control group (3.6 versus 2.6mEq/L, resp., P =
.029), and the median level of ARR was signiﬁcantly lower
in the SPECT/CT group than in the control group (18.7
versus 352.3, resp., P = .025). The median size of the aﬀected
adrenal gland on CT scan and pathological examination was
signiﬁcantly less in the SPECT/CT group than in the control
group (10.5 versus 18mm, resp., P = .007; 10 versus 20mm,
resp., P = .015). Compared with the control group, the
SPECT/CT group featured lower systolic BP (147mmHg)
and nonsuppressed PRA (1.47ng/mL/h) although the dif-
ference was not statistically signiﬁcant. Furthermore, both
groups had elevated PAC (32.1 versus 28.4ng/dL in the
control and SPECT/CT group, resp.) although the diﬀerence
was not statistically signiﬁcant.Journal of Biomedicine and Biotechnology 7
Table 3: Comparison of variables between the control and SPECT/CT groups.
Variable Control group (n = 9) SPECT/CT group (n = 6) P‡
Age (y)† 58 (32–72) 51 (27–57) .157
Male gender (n [%]) 2 (22%) 3 (50%) .329
Systolic BP (mmHg)† 180 (146–230) 147 (144–206) .077
Diastolic BP (mmHg)† 105 (71–130) 90 (80–115) .237
Serum potassium (mEq/L)† 2.6 (1.6–3.49) 3.6 (2.2–4.32) .029
PAC (ng/dL)† 32.1 (21.7–110.7) 28.4 (25.3–37.2) .239
PRA (ng/mL/h)† 0.06 (0.05–0.53) 1.47 (0.06–2.52) .058
Aldosterone-renin ratio (ARR)† 352.3 (23–642) 18.7 (13–447) .025
CT size (mm)† 18 (11–22) 10.5# (9–17#) .007
Pathological size (mm)† 20 (10–25) 10∗ (0.8–17∗) .015
A b b r e v i a t i o n sa r et h es a m ea sT a b l e s1a n d2.
†Data are expressed as median (range).
#n = 4; patients 10 and 15 were excluded in this variable because of normal appearance of adrenal glands on the CT scan.
∗n = 5; patient 15 was excluded in this variable because of bilateral adrenal hyperplasia.
‡P<. 05 as signiﬁcant.
4. Discussion
This is the ﬁrst study to report the use of NP-59 SPECT/CT
in patients with normal renal function and those with CKD
who are clinically suspected to have PA but have subtle
clinical symptoms, atypical results on screening tests, nega-
tive conﬁrmatory tests, or negative CT ﬁndings. This study
adds novel data to existing knowledge of PA by qualitatively
analyzing the associations between clinical symptoms and
screeningtests(Figure1),aswellasquantitativelycomparing
clinical and pathological parameters between control and
SPECT/CTgroups(Table3).First,ourﬁndingsshowthatthe
screening testing and conﬁrmatory testing may be unreliable
in subclinical PA characterized by stage 1 hypertension
without symptomatic hypokalemia, and in the setting of
CKD,andsecond,TheyshowthatNP-59SPECT/CTimaging
adds value in the diagnosis of probable PA when elevated
PAC and stage 1 or 2 hypertension coexists, but the other
criteria were not present.
The ﬁrst part of this study qualitatively analyzed the
application of NP-59 SPECT/CT in patients suspected of
havingPA,butclinicallynotconﬁrmed,asshowninFigure1.
Only 5 patients (patients 1–3, 5, and 8) presented with
typical clinical pictures, which lead to a rapid diagnosis.
Most of the patients presented with atypical signs and
symptoms: subclinical (stage 1 hypertension in the absence
of symptomatic hypokalemia) PA (n = 5), nonsuppressed
PRA (n = 9), negative ARR (n = 5), negative conﬁrmatory
tests (n = 4), and negative CT results (n = 2). This ﬁnding
is consistent with the viewpoint of Mosso et al. [19] that
PA should be considered a continuous pathological disorder,
in which most of the patients present with normokalemia
and a mild form, and only a minority of patients present
with a classical clinical picture of PA. Furthermore, it has
beenreportedthatthesalineloadingtestinghaslowaccuracy
in patients with normokalemic PA [9]. The lower right
area of Figure 1 corresponds to diﬃculty in arriving at
a diagnosis of PA because of subtle symptoms, atypical
screening testing, inclusive conﬁrmatory testing, or negative
CT ﬁndings and is where NP-59 SPECT/CT is useful because
it allows accurate localization of tumors because of its
high sensitivity and diagnostic accuracy [16]. Therefore, the
diagnosis of subclinical PA cannot rely on screening testing
and conﬁrmatory testing.
In addition, it is worth noting that 2 patients with CKD
(patients 12 and 15) were diagnosed with PA by means
of NP-59 SPECT/CT in this study. The diagnosis of PA
in patients with CKD is diﬃcult and easily missed, and
only 2 cases have been reported in the English literature
[20, 21]. This is because CKD masks the typical hallmarks
of PA (hypertension, hypokalemia, and low PRA), shares
some features with PA (such as hypertension and elevated
PAC) [22], and disturbs the renin-angiotension-aldosterone
system leading to a further decrease of the response of
renin/aldosteronetostimuliorsuppressivemanoeuvres[23].
Furthermore, PRA varies from low to high level [22], the
ARR is not reliable, and there are no clear-cut levels of PAC,
PRA, and ARR for the diagnosis of PA in patients with
CKD [4]. Adrenal vein sampling is more risky in patients
with CKD than in those with normal renal function. In
this setting, NP-59 SPECT/CT allows safe lateralization and
prompt decision-making.
The second part of our study analyzed the diﬀerences in
clinical and pathological parameters between the 2 groups,
as shown in Table 3. We found that patients using NP-
59 SPECT/CT imaging tended to feature stage 1 hyper-
tension (median BP, 147mmHg) and nonsuppressed PRA
(median level, 1.47ng/mL/h) and signiﬁcantly had negative
ARR, nearly normal serum potassium level, and smaller
adrenal size on CT imaging and pathological examination.
Taking together, patients with probable PA who required
NP-59 SPECT/CT imaging featured subclinical or atypical
presentations. We also found that PAC was elevated, but
not statistically signiﬁcant, in both groups, and that the
control group had higher PAC and systolic BP (median
level, 32.4ng/dL; median BP, 180mmHg, resp.) than the
SPECT/CT group (median level, 28.4ng/dL; median BP,
147mmHg, resp.). These ﬁndings implied that this clinical8 Journal of Biomedicine and Biotechnology
clue of stage 1 hypertension along with elevated PAC may
be useful when initially assessing the potential for subclinical
PA and that elevated PAC precedes evident hypertension
in patients with subclinical PA. It has been reported that
the existence of normotensive PA was featured as elevated
PAC [3]. Since PA is a continuous pathological disorder
[19] and prolonged hyperaldosteronism causes subsequent
hypertension [5] and excessive cardiovascular damage [6],
non-invasive NP-59 SPECT/CT can provide value for early
diagnosis and intervention of subclinical PA and may be a
reliable method to distinguish between patients with low-
renin essential hypertension and subclinical PA.
The Framingham oﬀspring study has shown that an
excess of circulating aldosterone in normotensive individuals
results in the development of sustained hypertension [5]a n d
cardiovascular morbidity and mortality that is beyond the
eﬀect of hypertension alone [6]. The cost eﬀectiveness of a
workup for subclinical PA remains to be determined. How-
ever, a timely identiﬁcation of subclinical PA is rewarding for
a number of reasons because a long-term cure implies saving
the costs of lifetime antihypertensive medications, testing
for monitoring the target organ damage, and treatment of
complications [24]. Furthermore, long-term cure rate of
hypertension correlates with the duration and severity of
hypertension and ranges from 30 to 60% [7]. In the present
study, 4 patients in the SPECT/CT group presented with
stage 1 hypertension and had cured hypertension, and 2
patients with stage 2 hypertension merely improved BP.
Therefore, vascular remodelling and duration of hyperten-
sion emphasize the importance of an early diagnosis of
subclinical or atypical features of PA for a more favorable
outcome.
The present study has some limitations. First, this was
a retrospective study, and conﬁrmatory testing and NP-
59 SPECT/CT were not performed in all patients. Second,
the speciﬁcity and diagnostic accuracy of NP-59 SPECT/CT
cannot be established because of the small number of cases.
Third, all patients did not undergo adrenal vein sampling.
5. Conclusion
In summary, our ﬁndings demonstrated that NP-59
SPECT/CT could be a reliable and non-invasive tool for an
early diagnosis of PA in patients with subclinical or atypical
features of PA and in CKD patients with suspected PA. NP-
59 SPECT/CT imaging may transform the diagnostic process
and lead to early identiﬁcation and prompt management of
these patients to achieve the cure of hypertension.
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